Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

HIV Infection

Free Subscription Articles published in Antivir Ther Retrieve available abstracts of 14 articles: HTML format

Single Articles

October 2026
1. SHEN Y, Huang EY, Yin O, Shiau S, et al
   Kidney function parameters in South African children living with HIV on antiretroviral therapy.
   Antivir Ther. 2026;31:13596535261490958.
   PubMed     Abstract available
   
   
   August 2026
2. PENNETZDORFER N, Naik V, Montezuma-Rusca JM, Sklar P, et al
   Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.
   Antivir Ther. 2026;31:13596535261481194.
   PubMed     Abstract available
   
   
   June 2026
3. PANNECOUCKE C, Valin N, Peytavin G, Lambert S, et al
   Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.
   Antivir Ther. 2026;31:13596535261436877.
   PubMed     Abstract available
   
   
   
4. EFRIDA, Yuza A
   Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.
   Antivir Ther. 2026;31:13596535261450699.
   PubMed     Abstract available
   
   
   April 2026
5. YOUNG J, Lawler PR, Moodie EEM, Bucher HC, et al
   It's about time: The association between abacavir and cardiovascular disease.
   Antivir Ther. 2026;31:13596535261438178.
   PubMed     Abstract available
   
   
   October 2025
6. DE KOFF EM, van Andel H, de Jong HK, van der Kooi AJ, et al
   Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
   Antivir Ther. 2025;30:13596535251385624.
   PubMed     Abstract available
   
   
   June 2025
7. GAO Y, Ji W, Chen Q
   The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis.
   Antivir Ther. 2025;30:13596535251345870.
   PubMed     Abstract available
   
   
   
8. VAN HEMELRYCK S, Van Landuyt E, Deleu S, Leopold L, et al
   Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1.
   Antivir Ther. 2025;30:13596535251349336.
   PubMed     Abstract available
   
   
   April 2025
9. ELEJE GU, Usman HA, Onubogu CU, Fiebai PO, et al
   Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort study.
   Antivir Ther. 2025;30:13596535251333259.
   PubMed     Abstract available
   
   
   
10. PALLANZA M, Thoueille P, Briki M, Alves Saldanha S, et al
    Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.
    Antivir Ther. 2025;30:13596535251335080.
    PubMed     Abstract available
    
    
    
11. LABATE L, Rossetti B, Russo C, Cassol C, et al
    Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database.
    Antivir Ther. 2025;30:13596535251317054.
    PubMed     Abstract available
    
    
    February 2025
12. PICKERING RT, Asundi A, Olson A, Soden K, et al
    Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir.
    Antivir Ther. 2025;30:13596535251314571.
    PubMed     Abstract available
    
    
    December 2024
13. PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al
    Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
    Antivir Ther. 2024;29:13596535241306467.
    PubMed     Abstract available
    
    
    April 2024
14. VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al
    Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using matching placebo tablets: A ran
    Antivir Ther. 2024;29:13596535241248282.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum